Kos settles Advicor name dispute with Andrx
Executive Summary
Andrx will end use of the Altocor name and pay $6 mil. to settle trademark dispute over Kos' cholesterol product Advicor. Settlement ends litigation in Philadelphia federal appeals court. Kos' original complaint in New Jersey federal court sought to enjoin Andrx from using Altocor name for its extended-release lovastatin; that motion was denied. Andrx will now market its product as Altoprev, a name approved by FDA in August 2003 (1"The Pink Sheet" May 10, 2004, In Brief)...
You may also be interested in...
Andrx changing Altocor name
Andrx is in discussions with FDA to market Altocor (lovastatin extended-release) under a new name "to avoid possible confusion in the marketplace." Company says name change is unrelated to Kos' lawsuit alleging a likelihood of confusion with its cholesterol-lowering agent Advicor (niacin/lovastatin). FDA already has approved Altoprev as an alternative brand for Altocor (1"The Pink Sheet" Sept. 15, 2003, In Brief)...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.